Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 30 November 2023, 15:25 HKT/SGT
Share:
    

Source: Eisai
Eisai's Sales Subsidiary Collaborates with Ministry of Public Health (MOPH) in Thailand

TOKYO, Nov 30, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that its Thai sales subsidiary Eisai (Thailand) Marketing Co., Ltd., (Eisai Thailand) has made an agreement to collaborate with the Department of Medical Services (DMS), Ministry of Public Health (MOPH) of Thailand to further enhance the access to treatments for dementia including Alzheimer’s disease (AD) in Thailand.

In Thailand, the number of people suffering from dementia is expected to increase significantly from the current 700 thousand to 2 million by 2050 due to the rapid aging of the population.*1 Dementia and AD are the third leading cause of death among women (7.1% of total deaths) and the ninth leading cause of death for men (3.3% of total deaths),*2 making the need to build a system to counter dementia urgent.

With this agreement, Eisai Thailand and DMS have identified three key challenges to addressing issues regarding dementia and AD in Thailand: (1) raising disease awareness for Mild Cognitive Impairment (MCI) and dementia including AD (2) improving diagnosis infrastructure for MCI and dementia including AD and ensuring civilian access to these services (3) ensuring total care by building a dementia community and ecosystem for people with dementia and their families.

Formulation of disease guidelines by the state is essential to address these challenges. Eisai Thailand and DMS will jointly conduct surveys and other initiatives to establish such guidelines. Additionally, both organizations will promote implementation of these guidelines in collaboration with various stakeholders, including those from different industries, to develop an ecosystem dedicated to dementia, seeking to establish a strong support system for the dementia community in Thailand.

Eisai will continue to support people with dementia and their families to “live their fullest lives” to effectively achieve social good in the form of “relieving anxiety over health” and “reducing health disparities”.

(1) Alzheimer’s Disease International. & Alzheimer’s Australia. (2014). Dementia in the Asia Pacific Region. London: Alzheimer’s Disease International.
(2) Burden of Disease Thailand Report 2019

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120




Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Sept 12, 2025 12:20 HKT/SGT
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
Sept 8, 2025 16:49 HKT/SGT
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
Sept 4, 2025 09:56 HKT/SGT
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025
Sept 3, 2025 10:32 HKT/SGT
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
Sept 1, 2025 12:44 HKT/SGT
FDA Approves LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Aug 29, 2025 17:17 HKT/SGT
Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma
Aug 25, 2025 18:30 HKT/SGT
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI(R) (lecanemab)
Aug 18, 2025 08:11 HKT/SGT
Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO(R) (Lemborexant) in China
July 31, 2025 17:27 HKT/SGT
Revenue of LEQEMBI(R) (Preliminary Basis)
July 31, 2025 08:30 HKT/SGT
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: